---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-025024"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:21:57.714538+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech receives Nasdaq non-compliance notice for board independence

## Summary
- Nasdaq notice dated Feb 13, 2024 due to insufficient independent directors after Alana McNulty's resignation.
- Board has 4 directors, only 2 independent; Audit Committee has only 2 independent members (needs 3).
- Cure period: until earlier of next annual meeting or Feb 4, 2025 (or Aug 2, 2024 if meeting before Aug 2).
- Company plans to elect one or more independent directors during cure period.
- No immediate effect on listing or trading of NKGN common or NKGNW warrants.

## SEC filing metadata
- accession: 0001104659-24-025024
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000110465924025024/0001104659-24-025024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000110465924025024/tm246575d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-025024
- JSON: https://secwatch.observer/filing/0001104659-24-025024.json
- Plain text: https://secwatch.observer/filing/0001104659-24-025024.txt

## Key facts
- Listing & Compliance Notices
  NKGen Biotech, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605, 5605(b)(1)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: board independence
  - Rules: 5605, 5605(b)(1)(A)
  source text: February 13, 2024, NKGen Biotech, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated February 13, 2024, indicating that, as a result of Alana McNulty’s resignation from the Board of Directors of the Company (the “Board”) and audit committee of the Board (the “Audit Committee”), effective February 4, 2024, that the Company is not currently in compliance with Nasdaq Listing Rule 5605, which requires that (i) a majority of the Board be comprised of independent directors and (ii) the Audit Committee is comprised of at least three indepen
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000110465924025024/0001104659-24-025024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.